1. Home
  2. DOGZ vs SPRO Comparison

DOGZ vs SPRO Comparison

Compare DOGZ & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DOGZ

Dogness (International) Corporation

HOLD

Current Price

$1.45

Market Cap

153.5M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.32

Market Cap

129.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOGZ
SPRO
Founded
2003
2013
Country
US
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.5M
129.6M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
DOGZ
SPRO
Price
$1.45
$2.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5M
300.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$47,977,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$0.51
52 Week High
$34.53
$3.09

Technical Indicators

Market Signals
Indicator
DOGZ
SPRO
Relative Strength Index (RSI) 19.41 48.98
Support Level $1.10 $2.30
Resistance Level $1.53 $2.44
Average True Range (ATR) 0.23 0.11
MACD 0.21 0.01
Stochastic Oscillator 37.19 61.54

Price Performance

Historical Comparison
DOGZ
SPRO

About DOGZ Dogness (International) Corporation

Dogness (International) Corp designs, manufactures pet products, including leashes and smart products, and lanyards. The company designs, processes, and manufactures fashionable and high-quality leashes, collars, and harnesses to complement cats' and dogs' appearances, as well as intelligent pet products. The company also provides dyeing services to external customers, as well as pet grooming services. The dyeing service is to utilize the existing production capacity and the pet grooming service is immaterial. Geographically, it generates maximum revenue from Mainland China and also has a presence in the United States, Europe, Australia, Canada, Central, and South America, Japan, and other Asian countries and regions.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: